Partners
Cellectis has established collaborations with leading biotechnology and pharmaceutical companies to advance genome engineering technologies across multiple therapeutic modalities
Cema-cel is a anti CD19 allogeneic CAR-T cells product candidate licensed to Servier under the License, Development and Commercialization Agreement signed by and between les Laboratoires Servier and Institut de Recherches Internationales Servier and Cellectis and sublicensed by Servier to Allogene in certain territories
US rights exclusively sublicensed to Allogene by Servier1
Exclusive worldwide licence to CD19-directed allogeneic CAR-T cells2
Financials:
340M In Development & Sales Milestones + Low Double-Digit Royalties on Sales
- The exclusivity is subject to the December 2025 Arbitral Decision.
- Servier grants to Allogene exclusive rights to cemacabtagene ansegedleucel in the U.S., EU and UK, and Allogene has been granted an option to extend its licensed territory to China and Japan subject to certain conditions
We have a License Agreement with Allogene Therapeutics, Inc., according to which we granted to Allogene an exclusive, worldwide license to develop and commercialize CAR T-cell products directed at a total of 15 selected targets* (including BCMA and CD70)1
Financials:
Up to $2.8B In Development & Sales Milestones + High Single-Digit Royalties on Sales
1. The exclusivity is subject to the December 2025 Arbitral Decision
We have a research collaboration and exclusive worldwide license agreement with Iovance Biotherapeutics, Inc. to develop gene-edited tumor-infiltrating lymphocytes (TILs)
Financials:
Undisclosed
We have a joint Research and Collaboration agreement to develop up to 10 novel products in oncology, immunology and rare diseases and investment agreement
Financials:
Up to $80M to $253M Per Product in Milestones + Tiered Royalties
Product Pipeline
Discover our product pipeline